Advertisement

PharmacoEconomics & Outcomes News

, Volume 818, Issue 1, pp 11–11 | Cite as

Capecitabine + bevacizumab in CRC: small benefit, high cost in US

Clinical study

Reference

  1. Sherman SK. et al. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer. JAMA Oncology : 29 Nov 2018. Available from: URL: http://dx.doi.org/10.1001/jamaoncol.2018.5070Google Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations